Tag: anti-SARS-CoV-2 plasma product
CSL Behring Australia Commences Development of Treatment for Serious Cases of COVID-19
Media Release
CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will begin immediate onshore development of an anti-SARS-CoV-2 plasma product with...
Featured Article
Don’t get left behind: Manufacturing’s urgent need for digital transformation
As digital transformation reshapes industries worldwide, manufacturers in Australia and beyond are finding themselves at the forefront of an evolution. This shift presents opportunities for companies looking to improve efficiency, drive innovation, and boost growth.
